Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Financing Activities (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Cash from Financing Activities for 12 consecutive years, with $14.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities changed N/A year-over-year to $14.4 million, compared with a TTM value of $81.6 million through Sep 2025, down 24.53%, and an annual FY2024 reading of $175.8 million, up 602.22% over the prior year.
  • Cash from Financing Activities was $14.4 million for Q3 2025 at Avalo Therapeutics, up from -$469000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $108.6 million in Q1 2024 and bottomed at -$14.8 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $20.5 million, with a median of $10.7 million recorded in 2023.
  • Peak annual rise in Cash from Financing Activities hit 6770800.0% in 2024, while the deepest fall reached 178.93% in 2024.
  • Year by year, Cash from Financing Activities stood at $76000.0 in 2021, then grew by 7.89% to $82000.0 in 2022, then crashed by 98.78% to $1000.0 in 2023, then soared by 6770800.0% to $67.7 million in 2024, then plummeted by 78.78% to $14.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AVTX at $14.4 million in Q3 2025, -$469000.0 in Q2 2025, and $67.7 million in Q4 2024.